Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

14.89 -0.62 (-4.00%)

Streaming Delayed Price Updated: 3:34 PM EDT, Jul 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Where Biohaven Pharma Hldgs Stands With Analysts ↗

August 03, 2021

Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the ...

Via Benzinga

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Stocks That Hit 52-Week Highs On Thursday ↗

July 29, 2021

Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new...

Via Benzinga

Analyst Ratings For Biohaven Pharma Hldgs ↗

July 16, 2021

Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:

Via Benzinga

Analyst Ratings For Biohaven Pharma Hldgs ↗

July 12, 2021

Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:

Via Benzinga

Analyst Ratings For Biohaven Pharma Hldgs ↗

July 08, 2021

Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) ...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO ↗

July 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...

Via Benzinga

Will This Biopharma Company Continue to Crush It? ↗

July 17, 2021

Migraine sufferers certainly hope so.

Via The Motley Fool

10 Biggest Price Target Changes For Monday ↗

July 12, 2021

RBC Capital boosted Chipotle Mexican Grill, Inc. (NYSE:C...

Via Benzinga

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗

July 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...

Via Benzinga

Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know ↗

July 07, 2021

Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminar...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 07, 2021

Gainers Opiant Pharmaceuticals (NASDAQ:OPNT

Via Benzinga

The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues ↗

July 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical...

Via Benzinga

Here's Why Biohaven Pharmaceutical Is Soaring Today ↗

July 07, 2021

Preliminary sales figures for the company's new migraine drug were much better than expected.

Via The Motley Fool

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

61 Biggest Movers From Yesterday ↗

July 08, 2021

Gainers Newegg Commerce, Inc. (NASDAQ: NEGG) shares surged 148.4% to close at $67.57 on Wednesday after jumping around 42% on Tuesday. Mannatech, Incorporated (NASDAQ: MTEX)...

Via Benzinga

Jim Cramer Says People Need To Know About Biohaven ↗

July 07, 2021

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced...

Via Benzinga

Biohaven Stock Hits Record High As Migraine Drug Trounces Quarterly Forecasts ↗

July 07, 2021

Biohaven crushed Wall Street's expectations for second-quarter sales of migraine drug Nurtec on Tuesday, leading BHVN stock to pop.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 07, 2021

Gainers Dare Bioscience (NASDAQ:DARE) shares increased by 51.97% to $2.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $...

Via Benzinga

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend ↗

July 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Biohaven Pharmaceutical: Return On Capital Employed Insights ↗

June 23, 2021

During Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $43.82 million. Despite a 28.93% in earnings, the company posted a loss of $235.88 million. In Q4, Biohaven...

Via Benzinga

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study ↗

June 15, 2021

Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical...

Via Benzinga

Biotechs Ready To Roar ↗

June 13, 2021

The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector...

Via Talk Markets

Biotech Movers During ASCO Week ↗

June 12, 2021

The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval.

Via Talk Markets

The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗

June 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,...

Via Benzinga

Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network

June 08, 2021

From Biohaven Pharmaceuticals

Via Business Wire

Biohaven Pharmaceutical Insights: Return On Capital Employed ↗

June 07, 2021

In Q1, Biohaven Pharmaceutical (NYSE:BHVN) posted sales of $43.82 million. Earnings were up 28.93%, but Biohaven Pharmaceutical still reported an overall loss of $235.88 million....

Via Benzinga

Analyst Ratings for Biohaven Pharma Hldgs ↗

June 01, 2021

Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.